The medication is a specialized supportive therapy commonly used to help with conditions involving functional stress on the liver. The combination is applied in clinical settings that involve acute and chronic forms of viral hepatitis and other liver diseases.

Support in Chronic Conditions and Symptom Relief

Phosphogliv is relevant for easing the overall symptom burden in long-standing conditions like Non-Alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease (ALD), and chronic viral hepatitis. It is used in situations involving progressive damage, and may assist with slowing the development of liver scarring (fibrosis), supporting the patient during episodes of heightened discomfort and preserving functional stability.

Mitigating Acute Stressors

The medication is commonly used to help with acute episodes of liver distress, such as drug-induced liver injury (DILI) caused by certain necessary drug treatments and acute viral hepatitis. It is applied in scenarios where temporary physiological imbalance has occurred due to toxins or intense viral activity, contributing to a supportive therapeutic benefit during these episodes and is intended to assist with maintaining functional stability.

Supports relief for Systemic Discomfort

Who Can and Cannot Use Phosphogliv?

The population eligibility rules for Phosphogliv are strictly defined by regulatory documentation, establishing specific contraindications and requirements for cautious use.

Absolute Contraindications (Must Not Use)

Contraindicated Group	Regulatory Basis
Hypersensitivity	Known allergy to Glycyrrhizinic Acid, Phosphatidylcholine, or excipients.
Antiphospholipid Syndrome (APS)	Explicitly prohibited due to comorbidity.
Pregnancy/Lactation	Contraindicated due to insufficient safety and efficacy data.

---

Age and Conditional Use Rules

Age-Related Eligibility:

• Oral Forms: Contraindicated in children younger than 12 years of age. Use is permitted for adolescents aged 12 and older.
• Intravenous Forms: Contraindicated for individuals younger than 18 years of age.

Conditional Use (Use with Caution):

Patients with Arterial Hypertension and Portal Hypertension require cautious use and clinical monitoring. These rules ensure that the medicine is reserved only for the population groups where its safety and efficacy profile have been sufficiently established or where risks can be mitigated.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Phosphogliv based primarily on the pharmacodynamic and pharmacokinetic properties of its active component, Glycyrrhizinic Acid.

Interaction Classifications and Restrictions

The co-administration of Phosphogliv with Glucocorticosteroids or Mineralocorticosteroids is formally classified as a contraindicated combination. This restriction is due to a significant pharmacodynamic potentiation effect, which increases the risk of severe side effects such as fluid retention and electrolyte imbalance.

Caution is formally required when combining the drug with potassium-losing diuretics (e.g., thiazides or loop diuretics) or certain laxatives. This is because the additive effect from both agents raises the risk of hypokalemia (abnormally low potassium levels).

Pharmacokinetic Interaction Potential

The active metabolite of Glycyrrhizinic Acid is documented to inhibit several major drug efflux transporters, including P-glycoprotein (P-gp), MRP1, MRP2, and BCRP. This inhibition may increase the systemic exposure and plasma concentration of other co-administered medicines that are substrates for these transporters. Additionally, regulatory literature notes the potential for the drug to alter the activity of the CYP3A enzyme family, which could influence the metabolism of CYP3A substrate medicines. The official prescribing context includes a mandatory restriction on alcohol consumption.

The pharmacological action of this fixed combination is defined by two distinct yet complementary pharmacodynamic domains: structural cellular repair and intensive inflammatory pathway modulation.

---

Cellular Membrane Stabilization and Structural Repair

This mechanism is driven by essential phospholipids (phosphatidylcholine), which are incorporated directly into the hepatocyte cell membranes. By physically replacing damaged lipids, the drug increases the membrane's integrity and fluidity, thereby stabilizing the cell structure and influencing the process of cytolysis (cell breakdown). This domain is a factor in cellular stability and the regenerative process of the liver cells.

Dual Modulation of Inflammation and Metabolic Pathways

The glycyrrhizinate component acts as a molecular modulator by suppressing the NF-κB inflammatory pathway and inhibiting the enzyme 11β-HSD2, which enhances local anti-inflammatory signaling. Concurrently, the phospholipid component activates the PPARα receptor and modulates SREBP, promoting fatty acid β-oxidation while suppressing new fat synthesis. This combined action modulates the inflammatory cascade and influences processes that decrease hepatic lipid accumulation.

The use protocol for Phosphogliv involves a two-phase administration strategy with distinct routes. The medicine is supplied as oral capsules and as a lyophilisate for preparing an intravenous (IV) solution, both for use in adolescents 12 years of age and older and adults.

Administration Scope

Instruction Entity	Description
Route of administration	The medicine is for Oral administration (capsules) and Intravenous (IV) administration (solution prepared from lyophilisate).
Dosing schedule	Oral: 2 capsules per dose. IV: 10 mL of prepared solution per dose.
Timing in relation to meals	Oral capsules are taken with food.
Preparation requirements	The lyophilisate is dissolved in 10 mL of Water for Injection. The resulting IV solution is administered slowly.
Age-group administration rules	The standard dosing regimen is for adults and adolescents 12 years of age and older.
Special procedural conditions	The total daily IV dose (20 mL) is administered in two separate administrations of 10 mL each. Oral capsules are swallowed whole.

---

Instruction Classifications

Classification	Description
Administration method type	Dual: Oral and Intravenous (IV).
Frequency pattern	Oral: 3 times per day (TID). IV: 2 times per day (BID).
Use-context constraints	Use follows a sequential pattern, beginning with an initial short-term course followed by long-term maintenance.

---

Resulting Procedural Structure

Standard sequence:

• Initial Phase: Administration of 10 mL of the reconstituted solution intravenously twice daily (BID), slowly, after preparation with Water for Injection.
• Duration Step: The intravenous administration phase typically lasts 10 days.
• Maintenance Phase: Transition to the oral capsule regimen, with 2 capsules taken three times daily (TID) with food.
• Long-term Duration: The oral administration period typically ranges between 3 and 6 months.

The protocol describes a sequence that starts with a short course of intravenous administration to initiate the therapy. This is followed by a sustained period of oral maintenance therapy. This regimen standardizes both the route and duration of administration, defining conditions such as required capsule intake timing and the splitting of the total daily IV dose.

Research Evidence / Overview of Studies for Phosphogliv

Evidence for Use in Liver Conditions

Research exploring the use of Phosphogliv in Alcoholic Liver Disease (ALD) and Non-Alcoholic Fatty Liver Disease (NAFLD) has involved both Randomized Controlled Trials (RCTs) and various observational studies. These trials primarily examine adult patients. Studies monitored several key indicators, including changes in liver enzyme biomarkers (ALT, AST, and GGT) and evaluated non-invasive measurement scores related to the appearance of liver scarring, or fibrosis. Findings describe patterns observed over short- to intermediate-term follow-up, typically six months or less.

Research also explored the combination for chronic viral hepatitis (such as B and C) and for Drug-Induced Liver Injury (DILI). Studies here typically used comparative designs, examining the medication's use as a supportive agent. Researchers monitored the decline and normalization of serum aminotransferase and bilirubin levels during these episodes.

Study Limitations and Gaps

The available evidence for Phosphogliv has limitations. Most of the dedicated research on this specific combination product was conducted within the Russian Federation and Eastern European countries, meaning the results apply only to the populations studied and may not fully reflect outcomes in other healthcare settings.

Long-term effects are not fully established. The research predominantly monitors indirect indicators, such as liver enzymes, over short time intervals. This means that robust evidence detailing the medication's relationship to hard clinical outcomes, such as progression to cirrhosis or the need for a liver transplant, is still emerging. Furthermore, data for specific subgroups, such as children or pregnant individuals, remains insufficient.

Common questions about Phosphogliv (FAQ)

Q: How quickly must the intravenous solution be administered?

According to the official prescribing information, the solution prepared for intravenous use should be administered slowly. The official product information does not specify the exact timeframe in minutes for administration.

Q: What specific diseases or conditions are absolute contraindications for using Phosphogliv?

Regulatory documents state that this medicine is officially not permitted for use (contraindicated) in people with a known hypersensitivity (allergy) to its components, or with Antiphospholipid Syndrome (APS). Contraindications also include severe pre-existing conditions such as severe arterial hypertension (high blood pressure) and severe hypokalemia (abnormally low potassium levels), and use during pregnancy or lactation.

Q: Does this medicine need to be refrigerated or is room temperature okay?

Official storage instructions state that the medicine must be stored at a temperature not exceeding 25 C. This temperature range aligns with standard room temperature conditions. Furthermore, the regulatory documents state the product must be kept in its original packaging and protected from light.

Q: What is the difference between the oral and the IV forms of the drug?

The oral and intravenous (IV) forms are used for different stages of the official administration regimen. The IV solution is used for the initial phase of therapy, followed by the oral capsules for the longer-term maintenance phase. The regulatory age limits also differ: the IV form is authorized for individuals 18 years and older, while the oral form is approved for adolescents 12 years and older.

Phosphogliv must be stored and handled according to the official requirements stated in the regulatory labeling to maintain its stability and effectiveness.

Official Storage and Handling

Requirement Category	Official Regulatory Statement
Storage Temperature:	Store the medicinal product at a temperature not exceeding 25 C.
Light Protection:	The product must be protected from light and kept in the original package.
In-Use Stability:	The solution prepared from the lyophilisate for intravenous use must be used immediately after reconstitution.
Child Safety:	Keep the product out of the reach of children.

Disposal Instructions

Unused or expired Phosphogliv must be disposed of in accordance with local regulatory requirements. The medicine is not officially categorized as hazardous pharmaceutical waste requiring special controlled disposal. General guidance advises against disposal by pouring down a sink or toilet.